BioSpace News Archive

Bristol-Myers Squibb has appointed Christopher Boerner to replace Murdo Gordon, who left the company on August 3. Boerner will take on the positions of executive vice president and chief commercial officer, effective immediately.

As President Donald Trump attempts to revise the North American Free Trade Agreement (NAFTA) between the U.S., Mexico and Canada, generic drugmakers have expressed concern over some of the negotiating points.

The U.S. Food and Drug Administration (FDA) warned four online networks that operate 21 websites selling opioids online. The warning indicates they were “illegally marketing potentially dangerous, unapproved, and misbranded versions of opioid medications, including tramadol.

Gilead Sciences announced the appointment of Laura Hamill as executive vice president, Worldwide Commercial Operations, and member of the company’s senior leadership team.

Top Wall Street biotech analysts are finding themselves in high demand, with staggering pay packages to go along with it, The Wall Street Journal reports.

Whether you’re a recent graduate about to embark on your career or a seasoned professional navigating the difficult waters of professional development and career pathing, a mentor can be an invaluable resource for career advice, support, connections, and encouragement.

Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and Development and a current senior partner at PureTech Ventures, responded to the editorial in Forbes. Let’s take a look.